Friday, January 20, 2017 3:06:30 AM
Posted by Cynthia Vaughn on Jan 19th, 2017 // No Comments
ADV MEDICAL ISO logoADV MEDICAL ISO (OTCMKTS:ADMD) CEO Michael K. Korenko purchased 700,000 shares of the business’s stock in a transaction dated Tuesday, January 17th. The shares were purchased at an average cost of $0.15 per share, with a total value of $105,000.00. Following the purchase, the chief executive officer now directly owns 130,000 shares in the company, valued at $19,500. The transaction was disclosed in a filing with the SEC, which is available through this hyperlink.
ADV MEDICAL ISO (OTCMKTS:ADMD) traded up 0.0000% on Thursday, hitting $0.1599. The stock had a trading volume of 2,300 shares. ADV MEDICAL ISO has a one year low of $0.07 and a one year high of $1.00. The stock has a 50-day moving average of $0.01 and a 200-day moving average of $0.01. The company’s market cap is $3.20 million.
About ADV MEDICAL ISO
Advanced Medical Isotope Corporation, formerly Savage Mountain Sports Corporation, is a radiation oncology focused medical device company. The Company is engaged in the development of yttrium-90 (Y-90)-based brachytherapy devices for the treatment of non-resectable tumors. Brachytherapy uses radiation to manage cancerous tumors by placing a radioactive isotope inside or next to the treatment area.
Recent RDGL News
- Form 8-K - Current report • Edgar (US Regulatory) • 12/27/2023 09:40:48 PM
- Form QUALIF - Notice of Qualification [Regulation A] • Edgar (US Regulatory) • 12/07/2023 05:15:10 AM
- Form 1-A POS - • Edgar (US Regulatory) • 11/27/2023 10:29:12 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 11/06/2023 04:28:46 PM
- Form 1-A POS - • Edgar (US Regulatory) • 11/03/2023 09:03:20 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 10/19/2023 04:18:34 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/11/2023 10:33:58 AM
- Form 1-A POS - • Edgar (US Regulatory) • 10/10/2023 04:05:36 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 08/04/2023 07:22:21 PM
NanoViricides Reports that the Phase I NV-387 Clinical Trial is Completed Successfully and Data Lock is Expected Soon • NNVC • May 2, 2024 10:07 AM
ILUS Files Form 10-K and Provides Shareholder Update • ILUS • May 2, 2024 8:52 AM
Avant Technologies Names New CEO Following Acquisition of Healthcare Technology and Data Integration Firm • AVAI • May 2, 2024 8:00 AM
Bantec Engaged in a Letter of Intent to Acquire a Small New Jersey Based Manufacturing Company • BANT • May 1, 2024 10:00 AM
Cannabix Technologies to Deliver Breath Logix Alcohol Screening Device to Australia • BLO • Apr 30, 2024 8:53 AM
Hydromer, Inc. Reports Preliminary Unaudited Financial Results for First Quarter 2024 • HYDI • Apr 29, 2024 9:10 AM